Hmdb loader
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2006-10-16 13:00:12 UTC
Update Date2022-03-07 02:49:25 UTC
HMDB IDHMDB0005012
Secondary Accession Numbers
  • HMDB05012
Metabolite Identification
Common NameOlanzapine
DescriptionOlanzapine was the third atypical antipsychotic to gain approval by the Food and Drug Administration (FDA) and has become one of the most commonly used atypical antipsychotics. Olanzapine has been approved by the FDA for the treatment of schizophrenia, acute mania in bipolar disorder, agitation associated with schizophrenia and bipolar disorder, and as maintenance treatment in bipolar disorder and psychotic depression. It has also been established in treating depression off-label because of its mood-stabilizing properties and its ability to increase the efficacy of antidepressants. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company. It is available as a pill that comes in the strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg and as as Zydis orally disintegrating tablets in the strengths of 5 mg, 10 mg, 15 mg, and 20 mg. It is also available as a rapid-acting intramuscular injection for short term acute use. Olanzapine (oh-LAN-za-peen, sold as Zyprexa, Zydis, or in combination with fluoxetine, as Symbyax) was the third atypical antipsychotic to gain approval by the Food and Drug Administration (FDA) and has become one of the most commonly used atypical antipsychotics. Olanzapine has been approved by the FDA for the treatment of schizophrenia, acute mania in bipolar disorder, agitation associated with schizophrenia and bipolar disorder, and as maintenance treatment in bipolar disorder and psychotic depression.
Structure
Data?1582752339
Synonyms
ValueSource
OlanzapinaChEBI
OlanzapinumChEBI
ZyprexaChEBI
LanzacHMDB
Zyprexa intramuscularHMDB
Zyprexa zydisHMDB
ZolafrenHMDB
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepineHMDB
Olanzapine pamoateHMDB
Chemical FormulaC17H20N4S
Average Molecular Weight312.432
Monoisotopic Molecular Weight312.14086735
IUPAC Name5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),3(7),5,8,10,12-hexaene
Traditional Namezyprexa
CAS Registry Number132539-06-1
SMILES
CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
InChI Identifier
InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
InChI KeyKVWDHTXUZHCGIO-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as benzodiazepines. These are organic compounds containing a benzene ring fused to either isomers of diazepine(unsaturated seven-member heterocycle with two nitrogen atoms replacing two carbon atoms).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub ClassNot Available
Direct ParentBenzodiazepines
Alternative Parents
Substituents
  • Benzodiazepine
  • Thieno-para-diazepine
  • 2,3,5-trisubstituted thiophene
  • Para-diazepine
  • N-methylpiperazine
  • N-alkylpiperazine
  • N-arylated-2-aminothiophene
  • 1,4-diazinane
  • Piperazine
  • 2-aminothiophene
  • Benzenoid
  • Imidolactam
  • Heteroaromatic compound
  • Thiophene
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Secondary amine
  • Amidine
  • Carboxylic acid amidine
  • Propargyl-type 1,3-dipolar organic compound
  • Organic 1,3-dipolar compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organic nitrogen compound
  • Amine
  • Organopnictogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Ontology
Physiological effect
Disposition
ProcessNot Available
Role
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic Properties

Experimental Collision Cross Sections

Adduct TypeData SourceCCS Value (Å2)Reference
[M+H]+CBM175.530932474
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.094 g/LALOGPS
logP3.61ALOGPS
logP3.39ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)14.17ChemAxon
pKa (Strongest Basic)7.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area30.87 ŲChemAxon
Rotatable Bond Count0ChemAxon
Refractivity93.87 m³·mol⁻¹ChemAxon
Polarizability35.37 ųChemAxon
Number of Rings4ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+173.43631661259
DarkChem[M-H]-173.54231661259
DeepCCS[M+H]+168.54330932474
DeepCCS[M-H]-166.18530932474
DeepCCS[M-2H]-199.16430932474
DeepCCS[M+Na]+174.63630932474
AllCCS[M+H]+172.632859911
AllCCS[M+H-H2O]+169.332859911
AllCCS[M+NH4]+175.632859911
AllCCS[M+Na]+176.432859911
AllCCS[M-H]-177.032859911
AllCCS[M+Na-2H]-176.532859911
AllCCS[M+HCOO]-176.132859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
OlanzapineCN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S23934.2Standard polar33892256
OlanzapineCN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S22632.0Standard non polar33892256
OlanzapineCN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S22788.6Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Olanzapine,1TMS,isomer #1CC1=CC2=C(S1)N([Si](C)(C)C)C1=CC=CC=C1N=C2N1CCN(C)CC12783.4Semi standard non polar33892256
Olanzapine,1TMS,isomer #1CC1=CC2=C(S1)N([Si](C)(C)C)C1=CC=CC=C1N=C2N1CCN(C)CC12712.8Standard non polar33892256
Olanzapine,1TMS,isomer #1CC1=CC2=C(S1)N([Si](C)(C)C)C1=CC=CC=C1N=C2N1CCN(C)CC13958.9Standard polar33892256
Olanzapine,1TBDMS,isomer #1CC1=CC2=C(S1)N([Si](C)(C)C(C)(C)C)C1=CC=CC=C1N=C2N1CCN(C)CC12934.8Semi standard non polar33892256
Olanzapine,1TBDMS,isomer #1CC1=CC2=C(S1)N([Si](C)(C)C(C)(C)C)C1=CC=CC=C1N=C2N1CCN(C)CC12915.9Standard non polar33892256
Olanzapine,1TBDMS,isomer #1CC1=CC2=C(S1)N([Si](C)(C)C(C)(C)C)C1=CC=CC=C1N=C2N1CCN(C)CC14032.0Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Olanzapine GC-MS (Non-derivatized) - 70eV, Positivesplash10-0btd-8090000000-3a1771a0db51f3e9472b2017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Olanzapine GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Olanzapine GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Experimental LC-MS/MSLC-MS/MS Spectrum - Olanzapine LC-ESI-qTof , Positive-QTOFsplash10-03dj-0940000000-1103f40c5bb833e129032017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Olanzapine LC-ESI-qTof , Positive-QTOFsplash10-03dj-0940000000-37cb2e8fb99c38b097b82017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Olanzapine LC-ESI-qTof , Positive-QTOFsplash10-0a4i-2790000000-bdc5a34b08715b752eef2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Olanzapine LC-ESI-QTOF , positive-QTOFsplash10-03di-0009000000-256a6e976b00468fe8392017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Olanzapine LC-ESI-QTOF , positive-QTOFsplash10-03di-0049000000-83ee647255e8d18f2b5c2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Olanzapine LC-ESI-QTOF , positive-QTOFsplash10-0a4i-0090000000-81810b42dccae4ee9ab62017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Olanzapine LC-ESI-QTOF , positive-QTOFsplash10-0bt9-0490000000-8994262c6a309d6637132017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Olanzapine LC-ESI-QTOF , positive-QTOFsplash10-01ot-0950000000-ceb0ca01cefbd1da57d72017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Olanzapine , positive-QTOFsplash10-03di-0149000000-e74851873e2fbaa6c1822017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Olanzapine , positive-QTOFsplash10-03dj-0940000000-1103f40c5bb833e129032017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Olanzapine , positive-QTOFsplash10-03dj-0940000000-37cb2e8fb99c38b097b82017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Olanzapine , positive-QTOFsplash10-03di-0149000000-338b982664cf3019be132017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Olanzapine , positive-QTOFsplash10-0a4i-2790000000-bdc5a34b08715b752eef2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Olanzapine 50V, Positive-QTOFsplash10-01ot-0950000000-fe416acb0e50253f8d172021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Olanzapine 40V, Positive-QTOFsplash10-0bt9-0490000000-a203abf5daf6a6c6e0692021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Olanzapine 20V, Positive-QTOFsplash10-03di-0049000000-4b7427c44443aab6c7a12021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Olanzapine 30V, Positive-QTOFsplash10-0a4i-0090000000-15b5422aefe3fc3729562021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Olanzapine 10V, Positive-QTOFsplash10-03di-0009000000-d71ce384c72fd5835dac2021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Olanzapine 50V, Positive-QTOFsplash10-01ot-0950000000-7ba8fbea8f79ae64960d2021-09-20HMDB team, MONAView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Olanzapine 10V, Positive-QTOFsplash10-03di-0019000000-66bcbe5560546ebe79ae2016-06-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Olanzapine 20V, Positive-QTOFsplash10-03di-0097000000-7386f41b1226646553902016-06-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Olanzapine 40V, Positive-QTOFsplash10-03k9-5980000000-82c2110f56cd7202848e2016-06-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Olanzapine 10V, Negative-QTOFsplash10-03di-0039000000-01aa4f818b0cb4798c0f2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Olanzapine 20V, Negative-QTOFsplash10-0300-0092000000-cee214399c7899dbbc412016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Olanzapine 40V, Negative-QTOFsplash10-0a6u-2490000000-dec2f8d13b50769ec96e2016-08-03Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Membrane (predicted from logP)
Biospecimen LocationsNot Available
Tissue Locations
  • Brain
  • Liver
Pathways
Normal Concentrations
Not Available
Abnormal Concentrations
Not Available
Predicted Concentrations
BiospecimenValueOriginal ageOriginal sexOriginal conditionComments
Blood0.000 uMAdult (>18 years old)BothNormalPredicted based on drug qualities
Blood0.000 umol/mmol creatinineAdult (>18 years old)BothNormalPredicted based on drug qualities
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB00334
Phenol Explorer Compound IDNot Available
FooDB IDFDB023585
KNApSAcK IDNot Available
Chemspider ID10442212
KEGG Compound IDC07322
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkOlanzapine
METLIN IDNot Available
PubChem Compound135398745
PDB IDNot Available
ChEBI ID7735
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferencePatel, Hiren V.; Ray, Anup K.; Patel, Pramod B.; Patel, Mahendra R. Process of preparation of olanzapine form I. PCT Int. Appl. (2003), 16 pp.
Material Safety Data Sheet (MSDS)Download (PDF)
General References
  1. Cerdan LF, Guevara MA, Sanz A, Amezcua C, Ramos-Loyo J: Brain electrical activity changes in treatment refractory schizophrenics after olanzapine treatment. Int J Psychophysiol. 2005 Jun;56(3):237-47. [PubMed:15866327 ]
  2. Horak EL, Jenkins AJ: Postmortem tissue distribution of olanzapine and citalopram in a drug intoxication. J Forensic Sci. 2005 May;50(3):679-81. [PubMed:15932107 ]
  3. Yamada K, Isotani T, Irisawa S, Yoshimura M, Tajika A, Yagyu T, Saito A, Kinoshita T: EEG Global Field Power spectrum changes after a single dose of atypical antipsychotics in healthy volunteers. Brain Topogr. 2004 Summer;16(4):281-5. [PubMed:15379228 ]
  4. Mortimer A, Martin S, Loo H, Peuskens J: A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol. 2004 Mar;19(2):63-9. [PubMed:15076013 ]
  5. Merrick TC, Felo JA, Jenkins AJ: Tissue distribution of olanzapine in a postmortem case. Am J Forensic Med Pathol. 2001 Sep;22(3):270-4. [PubMed:11563738 ]

Only showing the first 10 proteins. There are 14 proteins in total.

Enzymes

General function:
Involved in monooxygenase activity
Specific function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular weight:
58406.915
General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
This is one of the five types (D1 to D5) of receptors for dopamine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular weight:
50618.9
General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
This is one of the five types (D1 to D5) of receptors for dopamine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular weight:
48359.9
General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
This is one of the several different receptors for 5- hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. This receptor is involved in tracheal smooth muscle contraction, bronchoconstriction, and control of aldosterone production
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular weight:
52602.6
General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
This is one of the several different receptors for 5- hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular weight:
51820.7
General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular weight:
55783.6
General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular weight:
56835.4
General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
This is one of the five types (D1 to D5) of receptors for dopamine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular weight:
44224.3
General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular weight:
66127.4
General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
This is one of the five types (D1 to D5) of receptors for dopamine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular weight:
49292.8

Only showing the first 10 proteins. There are 14 proteins in total.